IOP Inc. - Specialty opthalmic surgical devices
Home Contact Us Site Map
IOP Inc. - Ophthalmic surgical devices IOP Inc. - Ophthalmic surgical product overview Educate surgeons on ophthalmic surgical devices Reimbursement for ophthalmic surgical technologies Information on Glaucoma, Eye Ptosis and Lagophthalmos Press Releases on ophthalmic surgical devices
Home » Surgeons and Medical Professionals » Biodome » Tech Data Tutoplast

Introduction

The exclusive Tutoplast® Process is a scientific and technology based method of virally inactivating, preserving and sterilizing human tissue for transplantation.

History

During the past thirty years, over 1 million Tutoplast® Bioimplants have been surgically implanted without a single documented case of disease transmission.

Stage 1: Materials - Source Screening Tutoplastâ human tissues are obtained from tissue banks operating in compliance with recovery standards set forth by the Food& Drug Administration and the AATB (American Association of Tissue Banks). Serological protocols are followed as consistent with current U.S. FDA requirements (serological testing includes HIV 1 and 2, Hepatitis B and C, among others). Source material is rejected if medical and/or social history indicates risk of infectious disease, malignancy or other disease. The tissues are placed in prepared storage medium before the onset of processing. All tissues are unambiguously labeled and must pass standards for size, structure, cleanliness and quality. No donor pooling is allowed.

Stage 2: Osmotic Cleaning and Acellularization Tissues are cleaned with saline solution of various concentrations. The result is the osmotic destruction of cells, reducing the tissue to its fiber and mineral components. The results of osmotic contrast bathing phase:

  • Removal of bacteria
  • Potential viruses are exposed and prepared for activation in following phase
  • Because the majority of antigens are bound to cell membranes, most of the antigenicity is removed

Stage 3: Viral Inactivation and Denaturization Inorganic agents (hydrogen peroxide, sodium hydroxide) are employed in specific concentrations during specific time intervals shown to inactivate HIV and the agent responsible for Creutzfeldt-Jakob Disease (CJD).1 This denaturization of soluble proteins is achieved without significant alterations in the collagenous structure of the tissue.

1. Brown P, et al. Sodium hydroxide decontamination of Creutzfeld-Jakob Disease virus. The New England Journal of Medicine. Vol. 310, No.11.

Stage 4: Tissue Preservation The tissue is preserved by the extraction of water using organic solvents (acetone). Through this gentle method of preservation, the dense collagenous tissue matrix of the tissue is retained. The organic solvents employed in Phase 1 and 2 of the tissue processing are completely removed, resulting in a residue-free allograft. The organic solvents employed during this stage also possess disinfectant properties capable of inactivating HIV and other unconventional viruses.2

2. Hinton R, Jinnah RH, Johnson C, et al. A biomechanical analysis of solvent-dehydrated and freeze-dried human fascia lata allografts. Am J Sports Med 1992;20: 607-612.

Stage 5: Terminal Sterilization Following dehydration, the tissue is configured to standard sizes and packaged in transparent, double peel pouches. Finally, the each tissue is terminally sterilized by gamma-irradiation. Since viral inactivation is achieved during the previous stages, an appropriate dosage is employed for effective terminal sterilization of any remaining bacteria or bioburden without significant effects on the collagenous, fibril structure of the tissue.

Histology

Tutoplast® Dura Mater - the Scaffold for Endogenous Tissue Growth.3

  • 14 days post-op: The graft is incorporated at the level of the skeletal striated muscle. It is surrounded by well-vascularized, cell-rich, unspecified granulation tissue composed of macrophages and fibroblasts.
  • 6 weeks post-op: The margins of the graft have become firmly incorporated in the host tissue where it has been replaced be cell-rich, well-vascularized endogenous connective tissue.
  • 14 months post-op: The former graft site exhibits a defined, irritation-free, greyish-shite sheet of collagenous tissue corresponding to viable endogenous connective tissue. No immunological rejection has been observed.

3. Hans-Jurgen Pesch. Solvent preserved grafts of dura mater and fascia lata (Membranous Collagen Graft) in animals. Facial Nerve 1984.


Product Overview
FIX 8™: Orbital Fixation System
IOPatch™: Patch Grafts
BioElevation™: Ptosis Slings
BioDome™: Implant Wraps
SutureGroove™: Gold Weights
AmbioDry2™: Amniotic Membrane
AmbioDry5™: Amniotic Membrane
Osmed™: Tissue Expanders
Molteno™: Glaucoma Implants

   Technology Resources:
Technical Data: Tutoplast® Process
Reference List
Ordering Information
Reimbursement
Directions for Use
Data Sheet/Brochure(Download PDF)


   Related Technologies:
IOPatch Ophthalmic Patch Grafts
BioElevation Ptosis Slings
SutureGroove Gold Eyelid Weights
Osmed Orbital Expanders
AmbioDry Amniotic Membrane